loading
Aclaris Therapeutics Inc stock is traded at $1.70, with a volume of 361.45K. It is up +1.19% in the last 24 hours and up +4.29% over the past month. Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
See More
Previous Close:
$1.68
Open:
$1.72
24h Volume:
361.45K
Relative Volume:
0.40
Market Cap:
$184.08M
Revenue:
$27.08M
Net Income/Loss:
$-37.00M
P/E Ratio:
-3.2692
EPS:
-0.52
Net Cash Flow:
$-18.46M
1W Performance:
+5.59%
1M Performance:
+4.29%
6M Performance:
-32.27%
1Y Performance:
+25.93%
1-Day Range:
Value
$1.665
$1.72
1-Week Range:
Value
$1.61
$1.78
52-Week Range:
Value
$1.05
$5.17

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name
Name
Aclaris Therapeutics Inc
Name
Phone
484-324-7933
Name
Address
701 LEE ROAD, WAYNE, PA
Name
Employee
64
Name
Twitter
@aclaristx
Name
Next Earnings Date
2025-02-24
Name
Latest SEC Filings
Name
ACRS's Discussions on Twitter

Compare ACRS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ACRS
Aclaris Therapeutics Inc
1.70 181.91M 27.08M -37.00M -18.46M -0.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-10-25 Resumed Piper Sandler Overweight
May-28-25 Initiated Wedbush Outperform
Mar-18-25 Resumed Cantor Fitzgerald Overweight
Dec-23-24 Upgrade H.C. Wainwright Neutral → Buy
Nov-20-24 Upgrade Cantor Fitzgerald Neutral → Overweight
Nov-19-24 Upgrade BTIG Research Neutral → Buy
Nov-19-24 Upgrade Jefferies Hold → Buy
Nov-19-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-18-24 Upgrade Piper Sandler Neutral → Overweight
Jan-22-24 Downgrade H.C. Wainwright Buy → Neutral
Nov-13-23 Downgrade William Blair Outperform → Mkt Perform
Oct-03-23 Initiated Evercore ISI Outperform
Dec-14-22 Initiated Stifel Buy
Dec-01-22 Initiated Goldman Buy
Oct-06-22 Initiated BTIG Research Buy
Jul-23-21 Resumed Jefferies Buy
Jun-15-21 Initiated Piper Sandler Overweight
Apr-21-21 Initiated H.C. Wainwright Buy
Oct-22-19 Upgrade SVB Leerink Mkt Perform → Outperform
Sep-06-19 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19 Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19 Initiated SVB Leerink Outperform
Mar-28-18 Resumed Leerink Partners Outperform
Feb-09-18 Initiated Guggenheim Buy
Jun-16-17 Initiated Cantor Fitzgerald Overweight
Nov-29-16 Initiated Leerink Partners Outperform
Sep-30-16 Initiated JMP Securities Mkt Outperform
Jun-10-16 Initiated Guggenheim Buy
Nov-02-15 Initiated Citigroup Buy
Nov-02-15 Initiated Jefferies Buy
View All

Aclaris Therapeutics Inc Stock (ACRS) Latest News

pulisher
Jul 25, 2025

What drives Aclaris Therapeutics Inc. stock priceRapidly expanding wealth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Aclaris Therapeutics Inc. Stock Analysis and ForecastConsistently high returns - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What institutions are buying Aclaris Therapeutics Inc. stock nowPhenomenal returns - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Aclaris Therapeutics Inc. stockFree Predictions - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Why Aclaris Therapeutics Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser

Jul 25, 2025
pulisher
Jul 23, 2025

LENZ Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital appreciation - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Aclaris Therapeutics Inc. a good long term investmentRapid capital growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

How Aclaris Therapeutics Inc. stock performs during market volatilityDaily Volume Leaders - Newser

Jul 22, 2025
pulisher
Jul 15, 2025

What makes Aclaris Therapeutics Inc. stock price move sharplyEntry Level Low Risk Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey

Jul 15, 2025
pulisher
Jul 12, 2025

Piper Sandler Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

Aclaris Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.50m - simplywall.st

Jul 11, 2025
pulisher
Jul 10, 2025

Plus Therapeutics (NASDAQ:PSTV) vs. Aclaris Therapeutics (NASDAQ:ACRS) Head-To-Head Survey - Defense World

Jul 10, 2025
pulisher
Jul 07, 2025

Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN

Jul 07, 2025
pulisher
Jul 07, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Jul 07, 2025
pulisher
Jun 30, 2025

Aclaris Therapeutics at HCW Conference: Strategic Moves and Future Plans By Investing.com - Investing.com Canada

Jun 30, 2025
pulisher
Jun 30, 2025

Aclaris Therapeutics joins Russell 3000 and Russell 2000 indexes - Investing.com

Jun 30, 2025
pulisher
Jun 30, 2025

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes - GlobeNewswire

Jun 30, 2025
pulisher
Jun 30, 2025

Aclaris Added to Russell Indexes: $10.6T in Benchmark Assets Now Track Biotech Stock - Stock Titan

Jun 30, 2025
pulisher
Jun 30, 2025

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Completeness Index - MarketScreener

Jun 30, 2025
pulisher
Jun 27, 2025

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference - The Manila Times

Jun 27, 2025
pulisher
Jun 26, 2025

Aclaris Therapeutics to Present at H.C. Wainwright Inflammation & Immunology Virtual Conference on June 30, 2025 - Nasdaq

Jun 26, 2025
pulisher
Jun 26, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Receives “Buy” Rating from HC Wainwright - Defense World

Jun 26, 2025
pulisher
Jun 25, 2025

Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 - MSN

Jun 25, 2025
pulisher
Jun 24, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Given Outperform Rating at Wedbush - Defense World

Jun 24, 2025
pulisher
Jun 19, 2025

Assenagon Asset Management S.A. Purchases 284,191 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Jun 19, 2025

Aclaris Therapeutics Inc Stock (ACRS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Aclaris Therapeutics Inc Stock (ACRS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Mehra Anand
Director
Nov 19 '24
Buy
2.25
666,666
1,499,998
710,030
Walker Neal
INTERIM PRESIDENT AND CEO
Aug 09 '24
Option Exercise
0.72
43,548
31,355
1,356,153
Leonard Braden Michael
10% Owner
Aug 05 '24
Buy
1.24
206,025
256,357
14,250,000
Leonard Braden Michael
10% Owner
Aug 02 '24
Buy
1.29
167,544
216,400
14,043,975
Leonard Braden Michael
10% Owner
Jul 30 '24
Buy
1.30
173,730
226,370
13,776,421
Leonard Braden Michael
10% Owner
Jul 31 '24
Buy
1.33
100,000
132,640
13,876,421
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):